Whenever ‘materials’, such as cell lines, anti-bodies, model systems (plants/animals), databases or other substances, are transferred from one institution or company to another, arrangements on the use of such materials should be covered in a material transfer agreement (MTA) .
The materials should only be used for the purpose the materials were released for. Furthermore, the materials are and continue to be the property of the party providing them. They may not be given to other parties without the consent of the providing party. As a general rule, the party providing the materials also provides a contract template to the second party.
MTA process for IXA VU and VUmc
To properly asses an MTA request, IXA requires you to fill out an intake form. This form contains all relevant information for the legal department to develop/review the agreement. If you have received an MTA from an external party, please include the draft MTA together with IXA’s intake form.
For non-biobank MTA’s, please download and fill in the appropriate intake form and send with the received MTA (if applicable) to IXA.
Optics11 and Optics11 Life have secured funding from Rabobank. The funding will be used to strongly accelerate growth across global markets, to further build the team for the future and to strategically expand the high-tech product portfolios of both business units. “This is the right moment to pick up the pace. Rabobank’s funding helps us […]News
Is it possible to create a cup of coffee that’s healthy and tasty? At the entrepreneurship laboratory Demonstrator Lab at the Vrije Universiteit, Florian Fermin (27) and Stefan Wateler (26) developed Cuppelement, a Fairtrade biodegradable coffee capsule with added superfoods and vitamins. During the Dutch TV program Dragons Den, the entrepreneurs successfully persuaded the dragons […]News
Azafaros B.V. announced today that the first cohort of healthy subjects has been dosed in a two-part Phase 1 clinical study with clinical candidate AZ-3102, a first-in-class small molecule compound being developed for the treatment of rare neurogenetic disorders. This double-blind, placebo-controlled, Phase 1 study is evaluating the safety and tolerability of ascending single- (SAD) […]News